Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
With the NICE approval and recommendation of the CardioQ-ODM, the potential for growth is huge. http://www.deltexmedical.com/latestnews.htm Regards
Deltex tipped by RHPS http://info.redhotpennyshares.co.uk/deltex_medical_just_hit_the_jackpot?gclid=CK7xh_Kw2KgCFUtC4QodqEeY-w&T=1304858548&JTID=146150423&OGID=52&network=GAW Regards
Good morning All, http://uk.reuters.com/business/quotes/overview?symbol=DEMG.L Regards
Quick-Buck, I tend to agree with you, regarding the placing and it's significance in relation to the share issue. One small point, it's not the monitors that sell for between £85 - £120, it's the disposable probes. Some times the monitors are given away, because the highest return is on the sale of disposables. BenBow, regarding the selling today - we don't know the identity of the seller(s). When a company places more shares in order to increase revenues, as DEMG maintain, it's not necessarily, a bad thing. If it were to pay off a debt, then it would be seen as a negative. The sp held up extremely well considering the millions of shares sold today. A resistant sp is a a good sign when considering an investment. The MM's had every opportunity to drop the sp today, but they didn't. I think this is a good sign, too. The fundamental for DEMG are excellent. The potential for raising revenue with this technology is immense. Patience is needed, as ever, and faith in the company. Remember, NICE, did not just approve the CardioQ-ODM, it recommended that the NHS adopt it. Regards and GLA
Deltex Med Grp PLC Issue of Equity RNS Number : 0370F Deltex Medical Group PLC 15 April 2011 Deltex Medical Group plc Additional Listing Deltex Medical Group plc (the 'Company') was notified today that certain of its current employees have acquired 490,105 ordinary shares of 1p each in the Company ("Ordinary Shares") as the result of the exercise of 490,105 options under the Company's 2003 Enterprise Management Incentive Scheme. Accordingly, application has been made for these Ordinary Shares to be admitted to trading on AIM. The shares will rank pari passu with the existing issued shares of the Company and dealings are expected to commence on 21 April 2011. Following this, the total number of voting rights in issue will be 137,831,893. For further information, please contact:- Deltex Medical Group plc 01243 774 837 Ewan Phillips, Chief Executive Paul Mitchell, Finance Director Nominated Adviser and Broker 0207 614 5917 Arden Partners plc Christopher Hardie Jamie Cameron This information is provided by RNS The company news service from the London Stock Exchange END
Friday 15 April, 2011 Deltex Med Grp PLC Issue of Equity RNS Number : 0343F Deltex Medical Group PLC 15 April 2011 Deltex Medical Group plc Placing of 3,684,211 New Ordinary Shares at 28.5 pence to raise approximately £1million 15 April 2011 - Deltex Medical Group plc ("Deltex Medical" or the "Company"), the global leader in oesophageal Doppler monitoring ("ODM"), announces that Arden Partners plc has on behalf of the Company, placed 3,684,211 new ordinary shares of 1 pence each ("New Ordinary Shares") at a price of 28.5 pence, to raise approximately £1 million after expenses (the "Placing"). The Company, which was cash positive at the operating level in the second half of 2010, will use the proceeds to strengthen its balance sheet following the National Institute for Health and Clinical Excellence (NICE) recommendation that the NHS in the UK adopt CardioQ-ODM™ in major and high risk surgery. The Directors expect that the NICE recommendation will stimulate sales growth and the Company is therefore taking this opportunity to raise further working capital in anticipation of this expected increase in demand. The Company estimates that at 31 December 2010 a CardioQ-ODM monitor was installed in approximately one-fifth of the NHS operating theatres used routinely for major and high risk surgery in England: in the year ended 31 December 2010 these monitors were used to treat approximately 3% of the 837,000 surgical patients identified by NICE. Placing details Arden Partners plc has placed 3,684,211 New Ordinary Shares on behalf of the Company with institutional investors. The Placing is conditional, inter alia, upon Admission and will raise approximately £1 million, after expenses. Application will be made for the New Ordinary Shares issued pursuant to the Placing to be admitted to trading on AIM and it is anticipated that Admission will become effective and that dealings will commence on 21 April 2011. The Placing Shares will, when issued, rank equally in all respects with the existing ordinary shares and will represent approximately 2.68 per cent. of the entire issued share capital of the Company immediately following Admission. Following the Placing the Company will have 137,341,788 ordinary shares in issue. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in Deltex Medical Group plc, under the Disclosure and Transparency Rules. ETC ETC
30/03/2011 NICE guidance opens a £65 million opportunity for Deltex; shares rocket Some of the market’s major winners will be companies that offer palpable cost savings to under-pressure public sector. A case in point is Deltex Medical, which has a device called CaridioQ that could save the National Health Service an estimated £1 billion a year. Huge potential here. Health care will always be a priority, and right now the need for the NHS to save money is a high priority. The CaridioQ offers the opportunity to reduce funding, whilst improving the care of patients . WIN -WIN! The market for this universal product is world wide and as the generated capital relies mainly upon the sale of consumable probes, the revenue remains regular and constant . If you're looking to invest, check it out... Regards
Guidance to NHS hospitals on costing the implementation of CardioQ -ODM: http://guidance.nice.org.uk/MTG3/CostingTemplate/xls/English Regards
http://www.digitallook.com/cgi-bin/dlmedia/security.cgi?username=&ac=&csi=14416 Regards
Good morning, I think there is / has been this week, a lot of profit taking. The reason for the fall is, as I see it, because the sp rose rapidly. Many who bought in when it was sub 20p, have opted out with their profit. Not all pi's buy into a company planning to hold long term. I wish I'd bought in when it was around 12p. I read about it in a financial review. I remember the author of the article (sorry can't remember any details), having listed and analysed numerous AIM shares, said if he had to pick one, it would be Deltex Medical. I then looked it up, but sadly didn't invest until it was over 20p. DEMG will probably need to produce some news to maintain any momentum on the share price. If the NHS place orders, or the Spanish hospitals where trials are currently in progress, do likewise, then we will should see good progress here. We mustn't forget that NICE, have recommended the use of the CardioQ -ODM in NHS hospitals. They normally follow such guidelines. We need to be patient (no pun intended) and see what the next few months bring. I imagine with the results and recommendations by NICE, after rigorous testing, DEMG could see world wide demand for its products. Hospitals are, after all, always out to improve patient care and save money. But it won's happen over night... Regards and all the best.
The sp has risen considerably in a short period of time. There's always a retrace. Don't panic. The fundamentals of this company are sound. There will be peaks and troughs along the way, but the journey will prove to be worthwhile. Regards and GL
http://www.h-l.co.uk/shares/stock-market-news/small-cap-news/cardio-boost-for-deltex-medical Regards
This might be interesting to those researching this company. Looks like an excellent investment opportunity. I was interested to read that it's the probes, not the monitors, that may well make the company most of its money. How much? Have a read and find out..... http://www.proactiveinvestors.co.uk/sponsors/472/deltex-medical-group-0472.html GLA
From RNS - Jan 26 2011 In addition the Company has been informed that yesterday, the following directors have also purchased Ordinary Shares in the market at a price of 2.75p per share, as follows: Name Number of Ordinary Shares purchased Total number of Ordinary Shares in which the director is now interested % Simon Cole bought - 300,000 holding - 21,575,064 12.07% Paul Pascoe bought 825,000 holding - 9,576,919 5.36 % * Thinking about it - If the company is in trouble, I don't think directors would have increased their share holding in January at 2.75p. These are now on a loss for them too. Guess we'll have to see how things pan out. GLA Regards
Wish I knew. Emailed the company regarding my ' buy ' not showing and the fact all trades are 'sells'. What do you make of its reply? Seems something odd is going on, but what? Comments, anyone...? Regards Hi ***, I don't understand why your buy has not registered. I can't give you any specific information that we are not giving to all shareholders - our results are due in June and there will probably be a standard trading statement sometime after the year end. thanks John
Looks like a good long term prospect. http://www.proactiveinvestors.co.uk/sponsors/1411/sarantel-group--1411.html Regards & GLA
If you look at the trading page, you will see that on the - 2-Feb-11 10:07:512. 7620,000 Sell* 2.753. 50552.00 (2.753p to sell) Between that date and today, according to the data, not a single share has been purchased. I purchased shares this morning for 2.75 - the same price! * My point is - if everyone has been selling, why has the price not fallen sharply over the last month? Clearly, there have been buys, only they are recorded as sells. It's a curious situation and it ill be interesting to see how things develop. Regards and GLA who enter...!
Just bought in @ 2.75p with Lloyds online dealing. GLA
Found as part of research into company. Not up to date, but interesting for those like me, wanting to find out about UBC. http://www.mediaweek.co.uk/news/1008155/UBC-Media-registers-40-rise-continuing-revenues/ Regards